The Column Group
QuietFiled to raiseSan Francisco, CABiotechnology, Pharmaceuticals, HealthcareLast fund filed 2025
2 on a current fund
last 24 months
across filed funds
| Vehicle | Filed | Target | Sold to date | Investors |
|---|---|---|---|---|
| Column Group Opportunity IVFiled to raise in 2025, with no closing reported yet. | 2025 | $600M | $0 | 0 |
| Column Group VIFiled to raise in 2025, with no closing reported yet. | 2025 | $600M | $0 | 0 |
| Column Group-Neuro II | February 2024 | $100M | $100M | 3 |
| Column Group Opportunity III | June 2022 | $600M | $600M | 100 |
Amounts are Item 13 as filed: the target is the whole offering, and the amount sold is cumulative across amendments rather than a final close. The filing carries no per-investor amount, so a firm’s own cheque is not recoverable here.
4 partners are named across this firm’s filings, 2 of them on a fund it is deploying now.
| Partner | Activity | Categories | Board seats | Last 24mo |
|---|---|---|---|---|
| David GoeddelNot on the current fund | Quiet | Biotech & pharma | 12 |
Classified sectors of The Column Group’s own portfolio companies, based on 19 with a verified or cited source.
Not a filing value: this is Lev’s own classification of each company, one company one vote regardless of how many of The Column Group’s partners are named on its board, shown only when we found a specific, checkable source. Companies with no source read as unclassified and are left out of the shares above.
| Firm | Shared boards | Companies |
|---|---|---|
| Caduceus Capital | 2 | Aragon Pharmaceuticals, IGENICA |
| Nextech Viii Carry Scsp | 2 | A2 Biotherapeutics, Hexagon Bio |
| Orbimed Asia Partners | 2 | Aragon Pharmaceuticals, IGENICA |
| Orbimed Genesis |
| Column Group V |
| June 2022 |
| $600M |
| $600M |
| 99 |
| Column Group-Neuro | May 2021 | $100M | $100M | 4 |
| Column Group IV-AFiled to raise in 2019, with no closing reported yet. | 2019 | $25M | $0 | 0 |
| Column Group IVFiled to raise in 2019, with no closing reported yet. | 2019 | $700M | $0 | 0 |
| Ponoi Capital IIFiled to raise in 2018, with no closing reported yet. | 2018 | $100M | $0 | 0 |
| PONOI CAPITALFiled to raise in 2017, with no closing reported yet. | 2017 | $150M | $0 | 0 |
| COLUMN GROUP III | April 2016 | $240M | $240M | 39 |
| COLUMN GROUP III-A | April 2016 | $271M | $271M | 32 |
| COLUMN GROUP II | April 2014 | $306M | $306M | 50 |
| 0 |
| Laurence LaskyNot on the current fund | Quiet | Biotech & pharma | 1 | 0 |
| Peter Svennilson | Quiet | Biotech & pharma | 8 | 0 |
| Tim Kutzkey | Quiet | Biotech & pharma | 8 | 0 |
Activity is filed board seats in the last 24 months: 4+ Active, 2–3 Selective, 1 Slowing, none Quiet. A firm's tier totals its partners, so an active firm may be four partners with one seat each. It undercounts partners who invest without taking a board seat, and filings lag a closing by weeks, so Quiet means the paperwork is quiet, not the person.
| 2 |
| Aragon Pharmaceuticals, IGENICA |
| Westlake Biopartners | 2 | Flexus Biosciences, RAPT Therapeutics |
| Abingworth Bioventures | 1 | EFFECTOR THERAPEUTICS |
| Lux Capital | 1 | Kallyope |
| Sofinnova Venture Partners | 1 | EFFECTOR THERAPEUTICS |
| Third Rock Ventures | 1 | CONSTELLATION PHARMACEUTICALS |
| U.S Venture Partners | 1 | EFFECTOR THERAPEUTICS |
| Versant Affiliates | 1 | Immune Design |
| Versant Venture Capital | 1 | Immune Design |
| Vida Ventures | 1 | A2 Biotherapeutics |
A shared board seat: a company where filings name a The Column Group partner and a partner at the other firm, both with a clean identity match. Not a claim either firm led or co-led the round, only that both are named on the same board.